Directorate Change-RENALYTIX PLC

Directorate Change-RENALYTIX PLC

Directorate Change

Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

LONDON and SALT LAKE CITY - July 3, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the appointment of Catherine Coste to the Company's Board of Directors, effective June 30, 2023. Ms. Coste was also appointed as the Non-Executive Chair of the Audit Committee and a member of the Renumeration Committee.

Ms. Coste has extensive financial experience having retired from Deloitte and Touche LLP ("Deloitte") in 2020, where she was a senior partner and served as one of Deloitte's life sciences industry executive leaders. She spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. Ms. Coste also has comprehensive public company board experience and currently serves as a director of both Minerva Surgical, Inc. where she serves as Chair of the Audit Committee and as member of the Compensation Committee, and Biomerica, Inc., where she is Chair of the Audit Committee, and serves on the Compensation Committee and the Nominating and Corporate Governance Committee. Ms. Coste also has extensive experience in Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls, and corporate governance. Ms. Coste is a Certified Public Accountant. Ms. Coste earned her B.A. in business administration, accounting, from California State University, Hayward.

James McCullough, Chief Executive Officer of Renalytix, commented: "Cathy brings important disciplines to Renalytix as we are expanding distribution for our just FDA approved KidneyIntelX to fight a disease effecting some 14 million American adults with diabetes and chronic kidney disease. Cathy's participation will allow us to maintain the high level of financial and risk compliance necessary to maximize a high-growth medical technology business in the United States and globally."

Cathy Coste said: "Catching patients early with high-risk kidney disease is key to reducing unnecessary suffering and controlling spiraling health care costs in diabetes. KidneyIntelX is uniquely positioned to set a new standard of care in chronic disease management, and I look forward to working closely with the management team and board at Renalytix to realize this opportunity."

Regulatory disclosure The following disclosures are made in accordance with Schedule 2(g) of the AIM Rules for Companies:

Catherine Havlik Coste, aged 57, holds no ordinary shares or options in the Company. Catherine Coste's current and previous directorships are as follows:

Current Directorships

Past Directorships / Partnerships (previous 5 years)

Biomerica, Inc.

Minerva Surgical, Inc.


Deloitte & Touche LLP (U.S.A)

Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.

No Comments

Post a Comment